Table 2.
Selected clinical trials yet to publish results.
| Trial | Intervention | N |
|---|---|---|
| Effect of “nicotinamide mononucleotide” (NMN) on cardiometabolic function (NMN) NCT03151239 |
NMN | 25 |
| Effect of long-term oral administration of nicotinamide mononucleotide (NMN) on human health UMIN000025739 |
NMN | 20 |
| Assessment of the safety of long-term nicotinamide mononucleotide (NMN). UMIN000030609 |
NMN | 30 |
| Evaluate the efficacy and safety of uthever NMN (nicotinamide mononucleotide, a form of vitamin B3) (NMN) NCT04228640 |
NMN | 66 |
| Effects of vitamin B3 derivative nicotinamide Riboside (NR) in bone, skeletal muscle and metabolic functions in aging NCT03818802 |
NR | 48 |
| Nicotinamide riboside for treating elevated systolic blood pressure and arterial stiffness in middle-aged and older adults NCT03821623 |
NR | 118 |
| Nicotinamide riboside in hospitalized patients NCT04110028 |
NR | 84 |
| The effects of nicotinamide adenine dinucleotide (NAD) on brain function and cognition (NAD) NCT02942888 |
NR | 46 |
| Crossover trial for nicotinamide riboside in subjective cognitive decline and mild cognitive impairment NCT04078178 |
NR | 40 |
| Evaluation of nicotinamide riboside in the prevention of small fiber axon degeneration and promotion of nerve regeneration NCT03912220 |
NR | 40 |
| NAD therapy for improving memory and brain blood flow in older adults with mild cognitive impairment NCT03482167 |
NR | 58 |
| A randomized controlled trial of nicotinamide supplementation in early Parkinson’s disease (NOPARK) NCT03568968 |
NR | 400 |
| NAD-supplementation in drug-naive Parkinson’s disease (NAD-PARK) NCT03816020 |
NR | 30 |
| Effects of vitamin B3 in patients with ataxia-telangiectasia NCT03962114 |
NR | 24 |
| Nicotinamide riboside in systolic heart failure NCT03423342 |
NR | 30 |
| Study to evaluate the effect of nicotinamide riboside on immunity NCT02812238 |
NR | 38 |
| Nicotinamide riboside and mitochondrial biogenesis NCT03432871 |
NR | 15 |
| Effects of nicotinamide riboside on the clinical outcome of Covid-19 in the elderly (NR-COVID19) NCT04407390 |
NR | 100 |
| A study to evaluate the safety and health benefits of Basis™ among elderly subjects. (15BSHE) NCT02678611 |
Basis (NR, pterostilbene) | 120 |
| A study by ChromaDex to assess the effects of TRU NIAGEN on cognitive function, mood and sleep in older adults NCT03562468 |
TRU NIAGEN (NR) | 40 |
| NAD Supplementation Study (NADS) NCT03310034 |
Nicotinic acid, nicotinamide, tryptophan |
14 |
| Nicotinamide as an early Alzheimer’s disease treatment (NEAT) NCT03061474 |
Niacin, nicotinamide | 48 |
| Study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA) NCT03761511 |
Nicotinamide | 225 |
| Niacin for Parkinson’s disease (NAPS) NCT03808961 |
Niacin | 100 |